Lo S - Search Results

1

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Pires da Silva I, et al. Among authors: lo s. J Immunother Cancer. 2022 Jul;10(7):e004610. doi: 10.1136/jitc-2022-004610. J Immunother Cancer. 2022. PMID: 35798536 Free PMC article.

2

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV. Menzies AM, et al. Among authors: lo s. Cancer. 2015 Nov 1;121(21):3826-35. doi: 10.1002/cncr.29586. Epub 2015 Jul 28. Cancer. 2015. PMID: 26218930 Free article.

3

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.

Itchins M, Ascierto PA, Menzies AM, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A. Itchins M, et al. Among authors: lo s. Melanoma Res. 2017 Jun;27(3):243-250. doi: 10.1097/CMR.0000000000000343. Melanoma Res. 2017. PMID: 28230715

4

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.

Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM. Choong ES, et al. Among authors: lo s. Eur J Cancer. 2017 Apr;75:169-178. doi: 10.1016/j.ejca.2017.01.007. Epub 2017 Feb 23. Eur J Cancer. 2017. PMID: 28236768

5

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA. Vilain RE, et al. Among authors: lo s. Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16. Clin Cancer Res. 2017. PMID: 28512174

6

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS. Parakh S, et al. Among authors: lo s. Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18. Br J Cancer. 2017. PMID: 28524161 Free PMC article.

7

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Lee JHJ, Lyle M, Menzies AM, Chan MMK, Lo S, Clements A, Carlino MS, Kefford RF, Long GV. Lee JHJ, et al. Among authors: lo s. Pigment Cell Melanoma Res. 2018 May;31(3):404-410. doi: 10.1111/pcmr.12675. Epub 2017 Dec 7. Pigment Cell Melanoma Res. 2018. PMID: 29171176 Clinical Trial.

8

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, Lo S, Hong AM, Menzies AM, Long GV. Tio M, et al. Among authors: lo s. Pigment Cell Melanoma Res. 2018 Jul;31(4):509-515. doi: 10.1111/pcmr.12682. Epub 2018 Jan 10. Pigment Cell Melanoma Res. 2018. PMID: 29277979 Clinical Trial.

9

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS. Lee JH, et al. Among authors: lo s. JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332. JAMA Oncol. 2018. PMID: 29423503 Free PMC article.

10

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Long GV, et al. Among authors: lo s. Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27. Lancet Oncol. 2018. PMID: 29602646 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,828 results

Search Page

Filters